[1]
AnL, ZengHM, ZhengRS, et al. [Liver cancer epidemiology in China, 2015][J]. Zhonghua Zhong Liu Za Zhi, 2019, 41(10): 721-727. DOI: 10.3760/cma.j.issn.0253-3766.2019.10.001.
[2]
中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌协会肝细胞癌专业委员会,北京医学会外科学分会肝脏学组,等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J]. 中华肝胆外科杂志,2021, 27(4): 241-251. DOI: 10.3760/cma.j.cn113884-20210415-00138.
[3]
HaberPK, PuigvehíM, CastetF, et al. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)[J]. Gastroenterology, 161(3): 879-898. DOI: 10.1053/j.gastro.2021.06.008.
[4]
中国抗癌协会肝细胞癌专业委员会转化治疗协作组. 肝细胞癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志,2021, 41(6): 618-632. DOI: 10.19538/j.cjps.issn1005-2208.2021.06.02.
[5]
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[6]
LiuY, WangY, GuoX, et al. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Revie and Network Meta-Analysis[J]. Front Oncol, 2021, 11: 709278. DOI: 10.3389/fonc.2021.709278.
[7]
ChawlaA, FerroneC. Hepatocellular Carcinoma Surgical Therapy: Perspectives on the Current Limits to Resection[J]. Chin Clin Oncol, 2018, 7(5): 48. DOI: 10.21037/cco.2018.08.12.
[8]
GallePR. The Current Landscape of Clinical Trials for Systemic Treatment of HCC[J]. Cancers, 2021, 13(8): 1962. DOI: 10.3390/cancers13081962.
[9]
BruixJ, TakayamaT, MazzaferroV, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16: 1344-1354. DOI: 10.1016/S1470-2045(15)00198-9.
[10]
EslamM, NewsomePN, AnsteeQM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[11]
DhamijaE, PaulSB, KediaS. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern[J]. Indian J Med Res, 2019, 149(1): 9-17. DOI: 10.4103/ijmr.IJMR_1456_17.
[12]
DuM, ChenL, ZhaoJ, et al. Microvascular invasion(MVI) is a poorer prognostic predictor for small hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 38. DOI: 10.1186/1471-2407-14-38.
[13]
LauwersGY, TerrisB, BalisUJ, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index[J]. Am J Surg Pathol, 2002, 26(1): 25-34. DOI: 10.1097/00000478-200201000-00003.
[14]
KangI, JangM, LeeJG, et al. Subclassification of Microscopic Vascular Invasion in Hepatocellular Carcinoma[J]. Ann Surg, 2021, 274(6): e1170-e1178. DOI: 10.1097/SLA.0000000000003781.
[15]
SimHW, KnoxJ. Hepatocellular carcinoma in the era of immunotherapy[J]. Curr Probl Cancer, 2018, 42(1): 40-48. DOI: 10.1016/j.currproblcancer.2017.10.007.
[16]
El-KhoueiryAB, SangroB, YauT, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
[17]
YauT, ParkJW, FinnRS, et al. Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial[J]. Lancet Oncol, 2022, 23(1): 77-90. DOI: 10.1016/S1470-2045(21)00604-5.
[18]
TopalianSL, TaubeJM, AndersRA, et al. Mechanism driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16(5): 275-287. DOI: 10.1038/nrc.2016.36.
[19]
AminiN, EjazA, SpolveratoG, et al. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review[J]. J Gastrointest Surg, 2014, 18(12): 2136-2148. DOI: 10.1007/s11605-014-2667-1.
[20]
中国医师协会外科医师分会,中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠外科学组,等. 中国结直肠癌肝转移诊断和综合治疗指南(2020版)[J]. 中国实用外科杂志,2021, 41(1): 11. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.01.